Abstract
With the rapid emergence of extended Field-of-View PET-cameras several new applications for radiopharmaceuticals become within reach. Main reason is the significant increase of the sensitivity of the PET-camera so that much less radioactivity can be administered. Issues that that hampered development or use of PET-radiopharmaceuticals become realistic again. Molar activity requirements can become less strict. New low-yielding radiochemistry methods may become applicable. Carbon-11 labelled compounds can revive and potentially be shipped to nearby PET-facilities. PET-radiopharmaceuticals with slow kinetics in comparison to their half life can still be used. As additional infrastructure and equipment will likely remain unchanged and keep the same sensitivity therefore there will be issues with kinetic modelling requiring analysis of plasma or metabolites samples with lower count rate. Besides the potential revival of failed radiopharmaceuticals, novel challenges are ahead to develop novel radiochemistry based on thus far unsuitable (low yielding or time consuming) reactions.
Original language | English |
---|---|
Article number | 70 |
Number of pages | 7 |
Journal | Cancer imaging |
Volume | 22 |
Issue number | 1 |
Early online date | 19-Dec-2022 |
DOIs | |
Publication status | Published - 19-Dec-2022 |
Keywords
- Extended field of view
- PET-camera
- PET-radiopharmaceutical
- Sensitivity